Datapoint: Xolair Scores FDA Nod for Food Allergies

Genentech and Novartis’ Xolair (omalizumab) on Feb. 16 became the first drug approved to prevent severe reactions from accidental exposure to multiple food allergies. Administered every two to four weeks, the injectable can be used in certain patients aged 1 and older to reduce the risk of severe reactions from IgE-mediated food allergies, such as allergies to peanuts, eggs and milk. Xolair was first approved in 2003 for the treatment of moderate to severe asthma. For this indication, it currently holds covered or better status for 83% of all insured lives under the pharmacy benefit, and 96% of lives under the medical benefit.

SOURCE: MMIT Analytics, as of  2/26/24

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 18

Datapoint: Texas Won’t Halt Latest Medicaid Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 17

Datapoint: Oscar Plans to Double Enrollment by 2027

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 13

Datapoint: Mississippi to Launch State-Run Exchange

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today